论文部分内容阅读
应用ＡＢＣ法、ＬＳＡＢ法对１４４例乳腺癌及癌旁组织进行了ｃ─ｅｒｂＢ─２、ｐ５３基因蛋白表达的研究。结果：ｃ─ｅｒｂＢ─２表达阳性率为４８．６％，浸润性导管癌阳性率最高（７４．１％）；其表达与肿瘤体积、淋巴结转移、组织分级、核分裂计数、临床分期呈正相关，与雌激素受体（ＥＲ）、孕激素受体（ＰＲ）状况呈负相关，表达者５年生存率显著低于表达阴性者．因而ｃ─ｅｒｂＢ─２表达的检测可作为评估乳腺癌预后的有力指标。ｐ５３表达的阳性率为２４．７％，髓样癌阳性率较高（３８．５％）；ｐ５３表达与组织分级和淋巴结转移状况呈正相关；阳性率随肿瘤体积增大和临床分期升高而增加；在ＥＲ或ＰＲ阴性者中ｐ５３阳性率高于ＥＲ或ＰＲ阳性者。本文未发现ｃ─ｅｒｂＢ─２与ｐ５３表达的相关性；两者表达均阳性者与仅一种阳性者在肿瘤体积、淋巴结转移和临床分期方面差异无显著性。
The expression of c-erbB-2 and p53 gene proteins in 144 cases of breast cancer and adjacent tissues was studied by ABC method and LSAB method. RESULTS: The positive rate of c-erbB-2 expression was 48.6%, and the positive rate of invasive ductal carcinoma was the highest (74.1%). The expression of c-erbB-2 was positively correlated with tumor volume, lymph node metastasis, tissue grading, mitotic count, and clinical stage. There was a negative correlation between estrogen receptor (ER) and progesterone receptor (PR) status, and the 5-year survival rate of the expression was significantly lower than that of negative expression. Therefore, c-erbB-2 expression can be used as a powerful indicator to evaluate the prognosis of breast cancer. The positive rate of p53 expression was 24.7%, and the positive rate of medullary carcinoma was high (38.5%). The expression of p53 was positively correlated with histological grade and lymph node metastasis. The positive rate increased with the increase of tumor size and clinical stage. The positive rate of p53 was higher in ER or PR negative than in ER or PR positive. No correlation between c-erbB-2 and p53 expression was found in this study. There was no significant difference in tumor volume, lymph node metastasis, and clinical stage between the positive and negative expressions.